---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-094522"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:23:41.640142+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio appoints Mark Guerin as CFO; base salary $450K plus options for 200K shares

## Summary
- Mark Guerin appointed CFO effective Sept 25, 2025; previously CFO of Onconova/Traws Pharma (TRAW).
- Compensation: $450K base salary, 40% annual target bonus, options for 200,000 shares, six months severance.
- Guerin holds CPA, CMA, CFM certifications; began career at Coopers & Lybrand.
- No transactions requiring disclosure under Item 404(a) between Guerin and the Company.

## SEC filing metadata
- accession: 0001104659-25-094522
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925094522/0001104659-25-094522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925094522/tm2527170d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-094522
- JSON: https://secwatch.observer/filing/0001104659-25-094522.json
- Plain text: https://secwatch.observer/filing/0001104659-25-094522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.